Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Fig. 4

The difference in time to radiologic progression (a) and survival (b) after dividing patients into 4 groups based on vascularity and HFSR-response; the difference in time to radiologic progression (c) and survival (d) after combining group B and C into group BC (Log-rank P < 0.001 for comparisons of all groups at the same time). Group A: patients with both hypervascularity and HFSR-response; group B: patients with hypervascularity but HFSR-nonresponse; group C: patients with hypovascularity but HFSR-response; group D patients with hypovascularity and HFSR-nonresponse; group BC: patients with either hypervascularity or HFSR-response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us